Education
About Us
Working with TipRanks
Follow Us
Neuropace, Inc. (NPCE)
NASDAQ:NPCE
NPCE Stock Chart & Stats
$14.09
-$0.66(-5.31%)
At close: 4:00 PM EST
$14.09
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)197.13K
Market Cap
$437.67M
Enterprise Value$486.81M
Total Cash (Recent Filing)$61.06M
Total Debt (Recent Filing)$70.84M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
May 07, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding33,666,946
10 Day Avg. Volume219,656
30 Day Avg. Volume197,127
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue4.87
Enterprise Value/Gross Profit6.30
Enterprise Value/Ebitda-35.28
Forecast
1Y Price Target
$19.33Price Target Upside37.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$99.09M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectoryNeuroPace has scaled revenue materially (Q3 2025: $27.4M, 30% YoY; RNS $22.6M), reflecting expanding adoption of the RNS system and broader geographic/program penetration. Sustained mid-20%+ growth supports durable market share gains and deeper clinical integration over months.
High Product-level Gross MarginsRNS product economics are strong (system gross margin >80%, corporate guidance ~76%–77%), implying durable unit profitability and attractive scalability. High gross margins allow incremental revenue to flow to operating leverage, helping improve operating results as scale continues.
Medicare Reimbursement TailwindCMS materially increased physician and hospital payments for initial implants and replacements, a structural change boosting procedure economics. Higher reimbursement supports broader neurosurgeon adoption, increases replacement revenue over time and underpins sustainable commercialization.
Bears Say
Elevated Leverage And Equity VolatilityLeverage has been a persistent constraint: debt stayed in the low-$70M range while equity was volatile, peaking D/E near 9.2x in 2024. Even after 2025 improvement, elevated leverage reduces financial flexibility, increasing refinancing and covenant risk if cash generation falters.
Persistent Negative Cash FlowOperating and free cash flow remain negative despite narrowing losses in 2025 (~-$11M), meaning the business still consumes cash. Continued cash burn increases the likelihood of external financing or dilution and limits ability to fund growth investments without raising capital.
Profitability Not Yet DurableAlthough adjusted EBITDA turned positive once, underlying accounting EBITDA/EBIT remain negative (2025 EBITDA margin ~-16%). Persistent net losses indicate profitability has not yet become durable, leaving the company reliant on operational improvements to sustain long-term self-funding.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $18.98 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $437.67M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on Mar 03, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.156 by $0.076.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 33,666,946 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.156. Following the earnings report the stock price went up 0.868%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.33 (37.19% Upside)
$19.33 (37.19% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 583.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.68%
12-Months-Change
Fundamentals
Return on Equity
-105.67%
Trailing 12-Months
Asset Growth
104.90%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, positive adjusted EBITDA, and increased guidance. There were challenges, including the winding down of the DIXI product line and extended timelines for pediatric indication, but these were outweighed by positive developments and strategic progress.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$19.33
▲(37.19% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
Currently, No data available
---